Scientific editorial illustration of a hydrophilic bile acid, endoplasmic-reticulum protein folding and a boundary between worm, mouse and human evidence
Geroprotect Blog

Geroprotect research note · Evidence review

TUDCA: A Bile Acid at the Proteostasis Frontier

Chemical-chaperone biology, human trials and what larger ALS studies did—and did not—show

Abstract

Tauroursodeoxycholic acid (TUDCA) is a taurine-conjugated, relatively hydrophilic bile acid studied as a modulator of protein folding, endoplasmic-reticulum stress, bile-acid composition and cell-death signalling. Its mechanistic literature is unusually broad. Its human evidence is much narrower.

A 20-person trial found improved clamp-measured hepatic and muscle insulin sensitivity after four weeks at 1,750 mg/day, without improvement in adipose insulin sensitivity or measured ER-stress markers. A 199-person primary-biliary-cholangitis trial found similar biochemical response rates for TUDCA and ursodeoxycholic acid over 24 weeks. In ALS, a 34-person TUDCA pilot was positive, but the subsequent European phase 3 TUDCA trial did not meet its primary or secondary endpoints. Separately, the sodium-phenylbutyrate–taurursodiol combination showed a positive phase 2 result and then failed its 664-person PHOENIX phase 3 trial. Those combination results cannot be assigned to TUDCA alone. Geroprotect Essentials II contains 360 mg per full six-tablet serving; no trial has tested that amount for healthy aging or the finished formula for proteostasis.

01 · Identity

A hydrophilic conjugated bile acid

TUDCA is the taurine conjugate of ursodeoxycholic acid (UDCA). Bile acids are cholesterol-derived molecules that support fat digestion, circulate between intestine and liver, and also act as signalling molecules. The 7β-hydroxyl configuration of UDCA and taurine conjugation make TUDCA relatively hydrophilic compared with several other bile acids.

That chemistry helps explain why TUDCA can alter membrane, protein-folding and stress responses in experimental systems. It also means that evidence from TUDCA should not be silently transferred to UDCA, an unconjugated bile acid used as a medicine, or to AMX0035, a fixed combination of taurursodiol and sodium phenylbutyrate.

02 · Human metabolic and liver evidence

Two controlled signals, both population-specific

Clamp-measured insulin sensitivity

Kars and colleagues randomised 20 adults with obesity and insulin resistance to placebo or 1,750 mg/day of TUDCA for four weeks. Hepatic and skeletal-muscle insulin sensitivity improved by about 30% in the TUDCA group, and muscle insulin-signalling measures increased. Adipose-tissue insulin sensitivity did not improve. Neither muscle nor adipose ER-stress markers changed, so the result did not confirm the assumed ER-stress mechanism in sampled human tissues.1

This is a technically strong physiological experiment with a very small sample, short duration and selected insulin-resistant population. It does not establish diabetes prevention, durable metabolic benefit or a healthy-aging effect.

Primary biliary cholangitis

A 24-week double-blind trial randomised 199 people with primary biliary cholangitis to 250 mg of TUDCA three times daily or the same schedule of UDCA. The prespecified response—more than a 25% alkaline-phosphatase reduction—occurred in 75.97% of the TUDCA group and 80.88% of the UDCA group (P=0.453). Both groups improved on several liver-chemistry measures and had comparable adverse-event rates.2

The absence of a statistically significant difference is not automatically proof of equivalence unless a non-inferiority framework and margin support that conclusion. More importantly, a cholestatic-disease trial does not validate supplementation in healthy adults.

03 · ALS: positive pilots, negative confirmation

The evidence changed when the trials became larger

An early double-blind pilot enrolled 34 people with ALS already receiving riluzole. TUDCA at 1 g twice daily for 54 weeks produced a higher prespecified responder proportion and more favourable ALSFRS-R results than placebo. The groups did not differ in adverse events.3 The small sample and unusual responder definition made replication essential.

The European TUDCA-ALS consortium then ran an 18-month, multicentre phase 3 trial of TUDCA added to standard therapy. Its March 2024 topline announcement reported that the trial missed the primary ALSFRS-R responder endpoint and found no statistically significant differences in secondary endpoints, including survival and neurofilament light. TUDCA was generally well tolerated, with predominantly mild gastrointestinal events in both groups.4 As of 14 July 2026, a peer-reviewed full-results paper was not identified; the conclusion here is therefore limited to the official consortium report.

AMX0035 is a different intervention

CENTAUR randomised 137 participants to placebo or a fixed combination of sodium phenylbutyrate and taurursodiol. Functional decline was slower on the combination over 24 weeks, while secondary outcomes did not significantly differ.5 PHOENIX was the larger confirmatory test: 664 participants, 48 weeks and 3:2 randomisation. The combination did not improve the primary change in ALSFRS-R versus placebo (P=0.667), and secondary endpoints were also not significant.6 US approval of Relyvrio was formally withdrawn in 2025 at the sponsor’s request following PHOENIX.7

PHOENIX cannot show whether taurursodiol, sodium phenylbutyrate, the combination logic or the disease context explains the null result. It does show why a mechanistically appealing combination cannot be described as clinically synergistic before confirmatory evidence.

04 · Mechanism and aging models

Proteostasis is plausible; translation remains open

In 2006, Özcan and colleagues showed that TUDCA and 4-phenylbutyrate reduced ER-stress signals and improved glucose homeostasis in obese diabetic mice.8 In HepG2 cells and cell-free protein assays, TUDCA reduced protein aggregation and altered the PERK–eIF2α–ATF4 arm of the unfolded-protein response without inducing CHOP, while protecting against several experimental stressors.9

A 2025 study reported that TUDCA bound HSP90, enhanced protein-refolding activity, extended lifespan in Caenorhabditis elegans, and improved exercise and cognitive measures in old mice.10 This is substantive preclinical geroscience. A worm lifespan and mouse performance experiment still cannot establish a human healthspan effect.

Not every model supports a broad chaperone explanation. In yeast, TUDCA rescued acute tunicamycin exposure even without a functional unfolded-protein response, but did not rescue other ER stressors or chronic misfolding models. The data indicated that TUDCA could reduce tunicamycin bioavailability at micelle-forming concentrations.11 The most accurate interpretation is therefore context-dependent modulation of proteostasis and stress biology—not a universal protein-refolding switch.

05 · Safety and interaction boundaries

Generally tolerable in trials, thin in long-term healthy use

Across the controlled studies discussed above, TUDCA was generally well tolerated. Gastrointestinal effects such as loose stools or abdominal discomfort are the most consistent practical signal, which is unsurprising for a bile-acid intervention. The PBC trial lasted 24 weeks, the small ALS pilot 54 weeks, and the metabolic trial four weeks. These populations, doses and monitoring protocols do not establish multi-year safety in healthy consumers.

AMX0035 safety data must remain attached to the combination. Its gastrointestinal event profile cannot be assigned exclusively to taurursodiol, and its sodium content and phenylbutyrate component are not properties of standalone TUDCA. Conversely, the negative PHOENIX efficacy result is not evidence that 360 mg of TUDCA in Geroprotect is harmful.

People with disorders that materially alter bile-acid circulation, pancreatic function or intestinal absorption, or who use prescription treatment for liver or biliary disease, need individual clinical review rather than a general supplement article. This is a standard context-specific precaution, not evidence of a common adverse event in healthy adults.

06 · Formula context

What 360 mg in Essentials II does—and does not—mean

A full six-tablet daily serving of Geroprotect Essentials II contains 360 mg of TUDCA (Tauroursodeoxycholic Acid). The labelled amount is below the 750–2,000 mg/day exposures used in the human disease and metabolic trials reviewed here. Lower exposure does not automatically mean proportionally lower effect, proven safety or equivalent pharmacokinetics.

No human study has tested TUDCA at 360 mg for a validated healthy-aging outcome. No component-controlled study has tested Essentials II, Essentials I plus Essentials II, or a TUDCA–spermidine, TUDCA–urolithin A or TUDCA–senolytic combination. The available evidence does not justify claims that TUDCA “pairs powerfully” with other actives, that it should be separated from fisetin or quercetin, or that HSP90 activity makes it antagonistic to senolysis. Those proposals require direct experiments.

StatementEvidence boundary
TUDCA modulates protein-stress biologySupported in cells and animals; the exact mechanism varies by model.
TUDCA improves human insulin sensitivityPositive in one 20-person, four-week study at 1,750 mg/day; replication and clinical outcomes are absent.
TUDCA treats ALSNot supported by phase 3 evidence. An early pilot was positive; the direct TUDCA phase 3 trial was primary-null.
AMX0035 validates TUDCANo. It is a combination intervention; phase 2 was positive and PHOENIX phase 3 was negative.
Essentials II improves proteostasisUnproven. No finished-formula trial has measured that outcome.

Questions

Frequently asked questions

Is TUDCA a proven chemical chaperone in humans?

“Chemical chaperone” describes a substantial cell and animal literature, but it is not a complete human mechanism. In the small insulin-sensitivity trial, metabolic physiology improved while measured muscle and adipose ER-stress markers did not.

Did the ALS trials support TUDCA?

The evidence changed with scale. A 34-person pilot was positive, but the subsequent direct TUDCA phase 3 trial missed its primary and secondary endpoints. The separate AMX0035 combination also moved from a positive phase 2 trial to a negative 664-person phase 3 trial.

Does the PHOENIX result prove TUDCA is ineffective?

No. PHOENIX tested sodium phenylbutyrate plus taurursodiol in ALS, so it cannot isolate either component. It does refute a clinical efficacy claim for that combination in that confirmatory trial.

Has 360 mg been shown to improve healthy aging?

No. The human studies used different doses in metabolic or disease populations, and the worm and mouse aging results are preclinical.

Should TUDCA be separated from senolytics?

No direct evidence reviewed here supports that instruction. Anti-apoptotic and HSP90 pathway reasoning can generate a hypothesis, but no study has shown that TUDCA blocks fisetin, quercetin or the Geroprotect formulas.

Sources

References

  1. Kars M, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59:1899–1905. DOI 10.2337/db10-0308.
  2. Ma H, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine. 2016;95:e5391. DOI 10.1097/MD.0000000000005391.
  3. Elia AE, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. European Journal of Neurology. 2016;23:45–52. DOI 10.1111/ene.12664.
  4. TUDCA-ALS Consortium. Announcement of topline results from the European phase 3 TUDCA-ALS trial. 27 March 2024. Trial NCT03800524.
  5. Paganoni S, et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. New England Journal of Medicine. 2020;383:919–930. DOI 10.1056/NEJMoa1916945.
  6. Amylyx Pharmaceuticals. Topline results from the 664-participant phase 3 PHOENIX trial of AMX0035. 8 March 2024. Trial NCT05021536. Sponsor report.
  7. US Food and Drug Administration. Relyvrio (sodium phenylbutyrate and taurursodiol): withdrawal of approval of new drug application. Federal Register. Effective 29 August 2025.
  8. Özcan U, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137–1140. DOI 10.1126/science.1128294.
  9. Uppala JK, et al. Chemical chaperone TUDCA, unlike PBA, mitigates protein aggregation efficiently and resists ER- and non-ER-stress-induced HepG2 cell death. Scientific Reports. 2017;7:3831. DOI 10.1038/s41598-017-03940-1.
  10. Liu JY, et al. Tauroursodeoxycholic acid targets HSP90 to promote protein homeostasis and extends healthy lifespan. Science China Life Sciences. 2025;68:416–430. DOI 10.1007/s11427-024-2717-6.
  11. Chasse MH, et al. TUDCA modulates drug bioavailability to regulate resistance to acute ER stress in Saccharomyces cerevisiae. Molecular Biology of the Cell. 2025;36:ar11. DOI 10.1091/mbc.E24-04-0147.

Quality you can check

Every badge links to the document behind it: manufacturer certificates, certificates of analysis for all 26 actives, and our own promises about the formula.

Huazhen Biotechnology (Shenzhen) holds ISO 22000:2018 certificate 015FSMS2400550 and HACCP certificate 015HACCP2400460, both valid until 2 December 2027. These are manufacturer system papers, not a product certificate. The earlier papers 150FSMS2200001 and 150HACCP2200001 ended in March 2025 and are not shown as valid. Halal certificates cover raw materials from our suppliers; Geroprotect Essentials is not registered as a halal product. Food supplement. Read the current product label before use.

Bought from Geroprotect? Leave an honest review:Review us on TrustpilotReview us on GoogleReview on Amazon.aeReviews are optional and never rewarded. More about reviews.
Scroll to Top